ALIVUS
LIFE SCIENCES
Evolve every day

August 18, 2026

To,	**To,**
Dy. General Manager	**The Manager – Listing,**
Department of Corporate Services,	**National Stock Exchange of India Ltd.,**
BSE Ltd.,	**Plot No. C/1, G Block,**
P. J. Towers, Dalal Street,	**Bandra Kurla Complex,**
Fort, Mumbai – 400 001	**Bandra (E), Mumbai – 400 051**
Ref: Scrip Code: 543322	**Ref: Scrip Name: ALIVUS**

Dear Sirs,

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")

In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with corresponding circulars and notifications issued thereunder, it is hereby informed to you that the Board of Directors of Alivus Life Sciences Limited at its meeting held on August 18, 2026, approved the share purchase agreement to acquire 76% stake in IQGEN-X Pharma Private Limited for an aggregate approx consideration INR 9.12 crores subject to adjustment as per Share purchase agreement.

The relevant disclosure as prescribed under Regulation 30 of the SEBI LODR Regulations and SEBI circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 is enclosed as Annexure 1.

You are requested to kindly takes note of the same.

Thanking You,

Your Sincerely,

For Alivus Life Sciences Limited
(formerly Glenmark Life Sciences Limited)

RUDALF JOSEPH CORRIEA

Digitally signed by RUDALF JOSEPH CORRIEA
Date: 2026.08.18 17:15:05 +05'30'

Rudalf Corriea
Company Secretary & Compliance Officer
Encl: As above

Annexure 1

S.No.	Particulars	Remarks
1.	Name of the target entity, details in brief such as size, turnover etc.	IQGEN-X Pharma Private Limited having its Registered Office at A-165, TTC Industrial Area, Khairane, Navi Mumbai 400705, Maharashtra, India Size- Authorised share capital Rs. 2,00,00,000/- divided into 20,00,000 equity shares of Rs.10/- each Turnover- INR 348 Lacs for financial year ended March 31, 2026.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	The acquisition does not fall within the related party transaction. No promoter has any interest in the entity being acquired.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	IQGEN-X Pharma Private Limited provides a wider spectrum for the Company to offer a complete end-to-end solution to its customers in both API and CDMO space.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No Government or regulatory approval required.
6.	Indicative time period for completion of the acquisition	December 6, 2026 or such date as may be agreed by the acquirer from the execution of the Share purchase Agreement (SPA), subject to fulfilment of Conditions Precedent in the SPA. The SPA provides that if the Condition Precedents are not met within the above said timelines from the execution, the sellers will enter into a Business Transfer Agreement with the Company whereby the entire business will be acquired by the Company from IQGEN-X Pharma Private Limited including the employees and assets.

7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	The aggregate consideration is approx INR 9.12 crores subject to customary adjustment as per SPA for acquisition of 8,60,589 equity shares of Rs.10/- each representing 76% of the paid up equity share capital of IQGEN-X Pharma Private Limited.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	76% of the paid-up equity share capital consisting of 8,60,589 equity shares of the face value of Rs.10/- each of IQGEN-X Pharma Private Limited.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	IQGEN-X Pharma Private Limited is a company incorporated under the Companies Act 2013 as a private limited company in Oct 2016. It is engaged in the business of formulation development of Oral Solids, Sterile Injectables and Ophthalmic solutions for regulated and semi regulated markets. Turnover of last 3 years 2025-26 INR 348.0 Lacs 2024-25 INR 318.2 Lacs 2023-24 INR 267.5 Lacs Country - India